Abstract
The accelerated cell cycle progression is one of the hallmarks of human cancer [...]
Highlights
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations
Therapeutic approaches aiming to directly suppress cell cycle motor functions have for long time been hampered by insufficient efficacy exhibited by inhibition or genetic deletion of individual cyclin-dependent kinase (CDK)
Palbociclib, abemaciclib and ribociclib have an indication in advanced breast cancers with recommendation of combination with endocrine therapy
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa 920-1192, Japan Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, Japan The accelerated cell cycle progression is one of the hallmarks of human cancer [1].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
